{
      "StudyFieldsResponse": {
            "APIVrs": "1.01.05",
            "DataVrs": "2022:10:06 23:25:58.836",
            "Expression": "mesenchymal stem Liver Cirrhosis",
            "NStudiesAvail": 430108,
            "NStudiesFound": 55,
            "MinRank": 1,
            "MaxRank": 1000,
            "NStudiesReturned": 55,
            "FieldList": [
                  "OverallOfficialName",
                  "OverallOfficialRole",
                  "OverallStatus",
                  "OversightHasDMC",
                  "PatientRegistry",
                  "Phase",
                  "PointOfContactEMail",
                  "PointOfContactOrganization",
                  "PointOfContactPhone",
                  "PointOfContactPhoneExt",
                  "PointOfContactTitle",
                  "PrimaryCompletionDate",
                  "PrimaryCompletionDateType",
                  "PrimaryOutcomeDescription",
                  "PrimaryOutcomeMeasure",
                  "NCTId"
            ],
            "StudyFields": [
                  {
                        "Rank": 1,
                        "OverallOfficialName": [
                              "ANANT E BAGUL, MS ORTHO"
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Unknown status"
                        ],
                        "OversightHasDMC": [
                              "No"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1",
                              "Phase 2"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "December 2014"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [
                              "1) Improvement of Liver Function tests liver functions( Albumin (ALB), Alanine aminotransferase (ALT), Aspartate Aminotransferase (AST), Prealbumin(PA), total bilirubin (TB), and direct bilirubin (DB) kidney function Blood urea nitrogen (BUN), Urea (UA), and Crea (Cr)),international normalized ratio (INR) in Liver Cirrhosis Patients"
                        ],
                        "PrimaryOutcomeMeasure": [
                              "Improvement in Liver function tests"
                        ],
                        "NCTId": [
                              "NCT01877759"
                        ]
                  },
                  {
                        "Rank": 2,
                        "OverallOfficialName": [
                              "Soon Koo Baik, M.D"
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Unknown status"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 2"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "June 2013"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [
                              "according to Metavir and Laennec fibrosis scoring system"
                        ],
                        "PrimaryOutcomeMeasure": [
                              "The improvement of Liver Histologic grade"
                        ],
                        "NCTId": [
                              "NCT01741090"
                        ]
                  },
                  {
                        "Rank": 3,
                        "OverallOfficialName": [
                              "Liem Nguyen, PHD"
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Recruiting"
                        ],
                        "OversightHasDMC": [],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "December 30, 2023"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [
                              "To assess safety: the number of AEs or SAEs during and after allogenic umbilical cord-mesenchymal stem cells (UC-MSCs) infusion"
                        ],
                        "PrimaryOutcomeMeasure": [
                              "Number of Adverse events and serious adverse events (AEs or SAEs)"
                        ],
                        "NCTId": [
                              "NCT05331872"
                        ]
                  },
                  {
                        "Rank": 4,
                        "OverallOfficialName": [],
                        "OverallOfficialRole": [],
                        "OverallStatus": [
                              "Unknown status"
                        ],
                        "OversightHasDMC": [
                              "No"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Not Applicable"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "June 30, 2019"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [
                              "Change of liver functions as assessed by MELD score (MELD, Model for End-Stage Liver Disease Score: MELD = 3.78\u00d7ln[serum bilirubin (mg/dL)] + 11.2\u00d7ln[INR] + 9.57\u00d7ln[serum creatinine (mg/dL)] + 6.43)",
                              "Adverse events as assessed according to CTCAE 4.03"
                        ],
                        "PrimaryOutcomeMeasure": [
                              "Efficacy: Change of liver functions as assessed by MELD score",
                              "Safety: Adverse events as assessed according to CTCAE 4.03"
                        ],
                        "NCTId": [
                              "NCT03209986"
                        ]
                  },
                  {
                        "Rank": 5,
                        "OverallOfficialName": [
                              "Xuetao Pei, MD,PhD",
                              "Yongjun Liu, MD,PhD",
                              "Mingyuan Wu, MD,PhD",
                              "Hanwei Li, MD,PhD",
                              "Liming Wang, MD",
                              "Xun Li, MD,PhD",
                              "Liming Chen, MD,PhD",
                              "Jianwei Lu, MD",
                              "Hui Shi, MD"
                        ],
                        "OverallOfficialRole": [
                              "Study Chair",
                              "Study Director",
                              "Study Director",
                              "Principal Investigator",
                              "Principal Investigator",
                              "Principal Investigator",
                              "Principal Investigator",
                              "Principal Investigator",
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Unknown status"
                        ],
                        "OversightHasDMC": [
                              "No"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1",
                              "Phase 2"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "July 2015"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [],
                        "PrimaryOutcomeMeasure": [
                              "survival time"
                        ],
                        "NCTId": [
                              "NCT01573923"
                        ]
                  },
                  {
                        "Rank": 6,
                        "OverallOfficialName": [
                              "murat kantarcioglu, MD"
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Unknown status"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Not Applicable"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "July 2012"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [
                              "biochemical and hematologic parameters"
                        ],
                        "PrimaryOutcomeMeasure": [
                              "clinical improvement"
                        ],
                        "NCTId": [
                              "NCT01499459"
                        ]
                  },
                  {
                        "Rank": 7,
                        "OverallOfficialName": [
                              "Chyntia O Jasirwan, PhD",
                              "Rima Haifa, B.Sc"
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator",
                              "Study Chair"
                        ],
                        "OverallStatus": [
                              "Recruiting"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1",
                              "Phase 2"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "June 20, 2023"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [
                              "a system for assessing the prognosis (including the required strength of treatment and necessity of liver transplant) of chronic liver disease, primarily cirrhosis. The score employs five clinical measures of liver disease.",
                              "a system for assessing the prognosis (including the required strength of treatment and necessity of liver transplant) of chronic liver disease, primarily cirrhosis. The score employs five clinical measures of liver disease.",
                              "a system for assessing the prognosis (including the required strength of treatment and necessity of liver transplant) of chronic liver disease, primarily cirrhosis. The score employs five clinical measures of liver disease.",
                              "assessed from SGOT and SGPT values in laboratory tests result",
                              "assessed from SGOT and SGPT values in laboratory tests result",
                              "assessed from SGOT and SGPT values in laboratory tests result",
                              "a scoring system for assessing the severity of chronic liver disease. MELD uses the patient's values for serum bilirubin, serum creatinine, and the international normalized ratio for prothrombin time (INR) to predict survival.",
                              "a scoring system for assessing the severity of chronic liver disease. MELD uses the patient's values for serum bilirubin, serum creatinine, and the international normalized ratio for prothrombin time (INR) to predict survival.",
                              "a scoring system for assessing the severity of chronic liver disease. MELD uses the patient's values for serum bilirubin, serum creatinine, and the international normalized ratio for prothrombin time (INR) to predict survival."
                        ],
                        "PrimaryOutcomeMeasure": [
                              "Child Pugh Score",
                              "Child Pugh Score",
                              "Child Pugh Score",
                              "Examination of liver function",
                              "Examination of liver function",
                              "Examination of liver function",
                              "MELD Score",
                              "MELD Score",
                              "MELD Score"
                        ],
                        "NCTId": [
                              "NCT04357600"
                        ]
                  },
                  {
                        "Rank": 8,
                        "OverallOfficialName": [
                              "Murat Kantarcioglu, M.D."
                        ],
                        "OverallOfficialRole": [
                              "Study Chair"
                        ],
                        "OverallStatus": [
                              "Unknown status"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1",
                              "Phase 2"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "July 2017"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [],
                        "PrimaryOutcomeMeasure": [
                              "All cause mortality"
                        ],
                        "NCTId": [
                              "NCT02705742"
                        ]
                  },
                  {
                        "Rank": 9,
                        "OverallOfficialName": [
                              "Jingbo Wang"
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Unknown status"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 2"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "December 31, 2019"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [
                              "The overall survival ratio of three groups will be detection after infusion in one year."
                        ],
                        "PrimaryOutcomeMeasure": [
                              "overall survival"
                        ],
                        "NCTId": [
                              "NCT03529136"
                        ]
                  },
                  {
                        "Rank": 10,
                        "OverallOfficialName": [
                              "Fu-Sheng Wang"
                        ],
                        "OverallOfficialRole": [
                              "Study Chair"
                        ],
                        "OverallStatus": [
                              "Recruiting"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 2"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "December 30, 2021"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [
                              "including the levels of albumin [ALB], prothrombin activity [PTA], total bilirubin [TBIL, and cholinesterase [CHE].",
                              "including infection, gastrointestinal bleeding, encephalopathy, and hepatorenal syndrome."
                        ],
                        "PrimaryOutcomeMeasure": [
                              "Liver function",
                              "The incidence of serious complications"
                        ],
                        "NCTId": [
                              "NCT03945487"
                        ]
                  },
                  {
                        "Rank": 11,
                        "OverallOfficialName": [
                              "Zibin Tian, MD"
                        ],
                        "OverallOfficialRole": [
                              "Study Director"
                        ],
                        "OverallStatus": [
                              "Unknown status"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1",
                              "Phase 2"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "October 2012"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [],
                        "PrimaryOutcomeMeasure": [
                              "The result of liver function and liver histological improvement."
                        ],
                        "NCTId": [
                              "NCT01224327"
                        ]
                  },
                  {
                        "Rank": 12,
                        "OverallOfficialName": [
                              "Liem Nguyen"
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Unknown status"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1",
                              "Phase 2"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "September 25, 2021"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [
                              "The PELD score is calculated using the following formula:\n\nPELD Score = 0.480 * ln (Bilirubin in mg/dL) + 1.857 * ln (INR) - 0.687 * ln (Albumin in g/dL) + 0.436 if the patient is <1 year old + 0.667 if there growth failure",
                              "Levels of albumin (g/dL)",
                              "Total bilirubin level (mg/dL)",
                              "Prothrombin time (second)",
                              "change of liver biopsy"
                        ],
                        "PrimaryOutcomeMeasure": [
                              "The change of PELD scores during study",
                              "The change of albumin (Liver function)",
                              "The change of total bilirubin (Liver function)",
                              "The change of prothrombin time",
                              "The change of liver biopsy"
                        ],
                        "NCTId": [
                              "NCT04522869"
                        ]
                  },
                  {
                        "Rank": 13,
                        "OverallOfficialName": [
                              "Chengwei Chen"
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Completed"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1",
                              "Phase 2"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "July 2011"
                        ],
                        "PrimaryCompletionDateType": [
                              "Actual"
                        ],
                        "PrimaryOutcomeDescription": [],
                        "PrimaryOutcomeMeasure": [
                              "Overall Survival (OS)"
                        ],
                        "NCTId": [
                              "NCT01342250"
                        ]
                  },
                  {
                        "Rank": 14,
                        "OverallOfficialName": [
                              "Yufang Shi, PhD,DVM",
                              "Jianhe Gan, MD"
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator",
                              "Study Chair"
                        ],
                        "OverallStatus": [
                              "Suspended"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1",
                              "Phase 2"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "December 2017"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [],
                        "PrimaryOutcomeMeasure": [
                              "The level of serum alanine aminotransferase (ALT\uff09",
                              "The level of serum total bilirubin (TB)",
                              "The level of serum prothrombin time (PT)",
                              "The level of serum prealbumin(PA)",
                              "The level of serum albumin (ALB)",
                              "Overall survival"
                        ],
                        "NCTId": [
                              "NCT01233102"
                        ]
                  },
                  {
                        "Rank": 15,
                        "OverallOfficialName": [
                              "Fu-Sheng Wang, MD, PhD"
                        ],
                        "OverallOfficialRole": [
                              "Study Chair"
                        ],
                        "OverallStatus": [
                              "Recruiting"
                        ],
                        "OversightHasDMC": [
                              "No"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "December 30, 2022"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [
                              "The Model for End-stage Liver Disease (MELD) is a scoring system that evaluates the liver function reserve and prognosis of patients with chronic liver disease by creatinine, international normalized ratio (INR), and bilirubin-conjugated cirrhosis etiology.\n\nThe MELD score is calculated by the formula: R = 9.6 \u00d7 ln (creatinine mg/dl) + 3.8 \u00d7 ln (bilirubin mg/dl) + 11.2 \u00d7 ln (INR) + 6.4 \u00d7 etiology, and the results are taken as integers. ( 0 for cholestatic and alcoholic cirrhosis and 1 for other causes of cirrhosis such as viruses)."
                        ],
                        "PrimaryOutcomeMeasure": [
                              "Incidence of Adverse Events Incidence of Adverse Events",
                              "Change in Model for End-Stage Liver Disease (MELD) score from baseline to 28th day"
                        ],
                        "NCTId": [
                              "NCT05227846"
                        ]
                  },
                  {
                        "Rank": 16,
                        "OverallOfficialName": [
                              "Dr. BV Tantry, MD., DM",
                              "Dr. Samir Shah, MD., DM",
                              "Dr. Dinesh Kini, MD., DM",
                              "Dr.Deepak N Amarapuraka, MD., DM",
                              "Dr. VA Saraswat, MD., DM",
                              "Dr. Aejaz Habeeb, MD., DM",
                              "Dr Uma Devi, MD",
                              "Dr Sanjay Kolte Kolte, DNB., FCPS",
                              "Dr Sandeep Nijhwan Nijhwan, MD., DM",
                              "Dr. Nitin Pai, MD., DM"
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator",
                              "Principal Investigator",
                              "Principal Investigator",
                              "Principal Investigator",
                              "Principal Investigator",
                              "Principal Investigator",
                              "Principal Investigator",
                              "Principal Investigator",
                              "Principal Investigator",
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Completed"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 2"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "April 2016"
                        ],
                        "PrimaryCompletionDateType": [
                              "Actual"
                        ],
                        "PrimaryOutcomeDescription": [
                              "The type of adverse events, number of adverse events and proportion of patients with adverse events"
                        ],
                        "PrimaryOutcomeMeasure": [
                              "Safety"
                        ],
                        "NCTId": [
                              "NCT01591200"
                        ]
                  },
                  {
                        "Rank": 17,
                        "OverallOfficialName": [
                              "Gang Chen, Professor"
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Unknown status"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "May 2016"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [
                              "According to National Cancer Institute Common Terminology Criteria for Adverse Events\uff08NCI-CTCAE)"
                        ],
                        "PrimaryOutcomeMeasure": [
                              "Severity of adverse events"
                        ],
                        "NCTId": [
                              "NCT02652351"
                        ]
                  },
                  {
                        "Rank": 18,
                        "OverallOfficialName": [
                              "Lin B liang, MD/PHD"
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Unknown status"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 2"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "October 2010"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [],
                        "PrimaryOutcomeMeasure": [
                              "The levels of serum alanine aminotransferase (ALT), total bilirubin (TB),prothrombin time (PT), albumin (ALB), prealbumin(PA), precollagen\u2162(PC\u2162), collagen\u2163(\u2163-C), laminin(LN), hyaluronidase(HN), liver histological improvement."
                        ],
                        "NCTId": [
                              "NCT00993941"
                        ]
                  },
                  {
                        "Rank": 19,
                        "OverallOfficialName": [
                              "Fengchun Zhang, MD",
                              "Robert Chunhua Zhao, MD,PhD"
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator",
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Unknown status"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "November 2013"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [
                              "Serum level of alkaline phosphatase will be measured at entry, 1 months\uff0c3 months, 6 months and 24 months after therapy"
                        ],
                        "PrimaryOutcomeMeasure": [
                              "serum level of alkaline phosphatase"
                        ],
                        "NCTId": [
                              "NCT01440309"
                        ]
                  },
                  {
                        "Rank": 20,
                        "OverallOfficialName": [
                              "Daiming Fan"
                        ],
                        "OverallOfficialRole": [
                              "Study Chair"
                        ],
                        "OverallStatus": [
                              "Unknown status"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1",
                              "Phase 2"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "September 2014"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [],
                        "PrimaryOutcomeMeasure": [
                              "one year survival rate"
                        ],
                        "NCTId": [
                              "NCT01728727"
                        ]
                  },
                  {
                        "Rank": 21,
                        "OverallOfficialName": [
                              "Zhu k shun, PHD"
                        ],
                        "OverallOfficialRole": [
                              "Study Director"
                        ],
                        "OverallStatus": [
                              "Unknown status"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 2"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "December 2009"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [],
                        "PrimaryOutcomeMeasure": [
                              "The levels of serum alanine aminotransferase (ALT), total bilirubin (TB), prothrombin time (PT), albumin (ALB)"
                        ],
                        "NCTId": [
                              "NCT00976287"
                        ]
                  },
                  {
                        "Rank": 22,
                        "OverallOfficialName": [
                              "Reza Malekzadeh, M.D",
                              "Ardeshir Ghavamzadeh, M.D.",
                              "Mehdi Mohamadnejad, M.D.",
                              "Kamran Alimoghaddam, M.D."
                        ],
                        "OverallOfficialRole": [
                              "Study Chair",
                              "Study Chair",
                              "Principal Investigator",
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Unknown status"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 2"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "August 2011"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [],
                        "PrimaryOutcomeMeasure": [
                              "MELD score, quality of life, liver volume, histological improvement (In a subset of patients with evidences of clinical and biochemical improvement, follow up liver biopsy will be performed at the end of follow up)."
                        ],
                        "NCTId": [
                              "NCT00476060"
                        ]
                  },
                  {
                        "Rank": 23,
                        "OverallOfficialName": [
                              "Mohammad Reza Zali, MD",
                              "Pedram Kharaziha, MD"
                        ],
                        "OverallOfficialRole": [
                              "Study Chair",
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Completed"
                        ],
                        "OversightHasDMC": [],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1",
                              "Phase 2"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "May 2009"
                        ],
                        "PrimaryCompletionDateType": [
                              "Actual"
                        ],
                        "PrimaryOutcomeDescription": [],
                        "PrimaryOutcomeMeasure": [
                              "Liver function test",
                              "MELD score"
                        ],
                        "NCTId": [
                              "NCT00420134"
                        ]
                  },
                  {
                        "Rank": 24,
                        "OverallOfficialName": [],
                        "OverallOfficialRole": [],
                        "OverallStatus": [
                              "Active, not recruiting"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 3"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "October 7, 2021"
                        ],
                        "PrimaryCompletionDateType": [
                              "Actual"
                        ],
                        "PrimaryOutcomeDescription": [
                              "The detect liver stiffness of significant or severe fibrosis (\u2265stage F2)\\(\u2265stage F3)",
                              "level of serum alanine aminotransferase less 40 (IU/L)",
                              "To observe for the following:\n\nabsence of grade IV anaphylactic reactions (in reference to CTCAE 4.03)",
                              "The level of glomerular filtration range from 90 to 120 mL/min/1.73 m2"
                        ],
                        "PrimaryOutcomeMeasure": [
                              "MR Elastography",
                              "The level of serum alanine aminotransferase (ALT)",
                              "Clinical Examination",
                              "The level of glomerular filtration rate (GFR)"
                        ],
                        "NCTId": [
                              "NCT05080465"
                        ]
                  },
                  {
                        "Rank": 25,
                        "OverallOfficialName": [],
                        "OverallOfficialRole": [],
                        "OverallStatus": [
                              "Unknown status"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1",
                              "Phase 2"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "June 2017"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [],
                        "PrimaryOutcomeMeasure": [
                              "Improvement of liver function in form of improvement in child score"
                        ],
                        "NCTId": [
                              "NCT02943889"
                        ]
                  },
                  {
                        "Rank": 26,
                        "OverallOfficialName": [
                              "Charlie Xiang, Professor"
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Unknown status"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1",
                              "Phase 2"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "October 2013"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [],
                        "PrimaryOutcomeMeasure": [
                              "Overall Survival"
                        ],
                        "NCTId": [
                              "NCT01483248"
                        ]
                  },
                  {
                        "Rank": 27,
                        "OverallOfficialName": [
                              "Fangyu Wang, MD/PhD",
                              "Fangyu Wang, MD/PhD"
                        ],
                        "OverallOfficialRole": [
                              "Study Director",
                              "Study Director"
                        ],
                        "OverallStatus": [
                              "Unknown status"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 3"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "January 2014"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [],
                        "PrimaryOutcomeMeasure": [
                              "change in immune function,liver function in blood"
                        ],
                        "NCTId": [
                              "NCT01854125"
                        ]
                  },
                  {
                        "Rank": 28,
                        "OverallOfficialName": [
                              "Teo Cheng Peng",
                              "Wai Chun Tao, Desmond",
                              "Lee Kang Hoe"
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator",
                              "Principal Investigator",
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Recruiting"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1",
                              "Phase 2"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "October 22, 2021"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [
                              "To observe for the following:\n\nabsence of grade IV anaphylactic reactions (in reference to CTCAE 4.03)\nabsence of grade IV febrile reactions or septic/ infective complications (in reference to CTCAE 4.03).",
                              "To detect liver stiffness",
                              "To ensure the absence of deterioration of liver function.",
                              "To ensure the absence of deterioration of renal function."
                        ],
                        "PrimaryOutcomeMeasure": [
                              "Clinical Examination",
                              "MR Elastography",
                              "The level of serum alanine aminotransferase (ALT)",
                              "The level of glomerular filtration rate (GFR)"
                        ],
                        "NCTId": [
                              "NCT03626090"
                        ]
                  },
                  {
                        "Rank": 29,
                        "OverallOfficialName": [
                              "Fu-Sheng Wang, MD, PhD"
                        ],
                        "OverallOfficialRole": [
                              "Study Chair"
                        ],
                        "OverallStatus": [
                              "Recruiting"
                        ],
                        "OversightHasDMC": [
                              "No"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 2"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "June 30, 2023"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [
                              "The Model for End-stage Liver Disease (MELD) is a scoring system that evaluates the liver function reserve and prognosis of patients with chronic liver disease by creatinine, international normalized ratio (INR), and bilirubin-conjugated cirrhosis etiology.\n\nThe MELD score is calculated by the formula: R = 9.6 \u00d7 ln (creatinine mg/dl) + 3.8 \u00d7 ln (bilirubin mg/dl) + 11.2 \u00d7 ln (INR) + 6.4 \u00d7 etiology, and the results are taken as integers. ( 0 for cholestatic and alcoholic cirrhosis and 1 for other causes of cirrhosis such as viruses)."
                        ],
                        "PrimaryOutcomeMeasure": [
                              "Change in Model for End-Stage Liver Disease (MELD) score from baseline to 24th week"
                        ],
                        "NCTId": [
                              "NCT05121870"
                        ]
                  },
                  {
                        "Rank": 30,
                        "OverallOfficialName": [
                              "Fu-Sheng Wang, MD, PhD"
                        ],
                        "OverallOfficialRole": [
                              "Study Chair"
                        ],
                        "OverallStatus": [
                              "Not yet recruiting"
                        ],
                        "OversightHasDMC": [
                              "No"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 2"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "December 31, 2023"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [
                              "The Model for End-stage Liver Disease (MELD) is a scoring system that evaluates the liver function reserve and prognosis of patients with chronic liver disease by creatinine, international normalized ratio (INR), and bilirubin-conjugated cirrhosis etiology."
                        ],
                        "PrimaryOutcomeMeasure": [
                              "Change in Model for End-Stage Liver Disease (MELD) score from baseline to 24th week"
                        ],
                        "NCTId": [
                              "NCT05224960"
                        ]
                  },
                  {
                        "Rank": 31,
                        "OverallOfficialName": [
                              "Shuji Terai, MD"
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Recruiting"
                        ],
                        "OversightHasDMC": [],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1",
                              "Phase 2"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "June 2022"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [
                              "Safety will be evaluated based on the medical review of adverse event reports and the results of clinical laboratory tests, vital sign, and physical examinations.",
                              "Improvement rate of Child-Pugh score from the baseline will be evaluated."
                        ],
                        "PrimaryOutcomeMeasure": [
                              "Safety profile of ADR-001 including the incidence of adverse events (Phase 1)",
                              "Improvement rate of Child-Pugh score (Phase 2)"
                        ],
                        "NCTId": [
                              "NCT03254758"
                        ]
                  },
                  {
                        "Rank": 32,
                        "OverallOfficialName": [
                              "Xuegong Fan, doctor"
                        ],
                        "OverallOfficialRole": [
                              "Study Director"
                        ],
                        "OverallStatus": [
                              "Recruiting"
                        ],
                        "OversightHasDMC": [],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "December 2022"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [
                              "After finish the mesenchymal stem cell treatment, observe the change in baseline outcome measures.\n\n40 or more - 71.3% observed mortality 30-39 - 52.6% observed mortality 20-29 - 19.6% observed mortality 10-19 - 6.0% observed mortality <9 - 1.9% observed mortality"
                        ],
                        "PrimaryOutcomeMeasure": [
                              "Validity evaluation by detection of the Model for end-stage Liver Disease score of participants"
                        ],
                        "NCTId": [
                              "NCT03826433"
                        ]
                  },
                  {
                        "Rank": 33,
                        "OverallOfficialName": [
                              "Soon Koo Baik, M.D.,Ph.D",
                              "Si-Hyun Bae, M.D.,Ph.D"
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator",
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Completed"
                        ],
                        "OversightHasDMC": [],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 2"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "March 2016"
                        ],
                        "PrimaryCompletionDateType": [
                              "Actual"
                        ],
                        "PrimaryOutcomeDescription": [],
                        "PrimaryOutcomeMeasure": [
                              "Histopathological evaluation (Fibrosis Grade - Laennec Scoring System)"
                        ],
                        "NCTId": [
                              "NCT01875081"
                        ]
                  },
                  {
                        "Rank": 34,
                        "OverallOfficialName": [],
                        "OverallOfficialRole": [],
                        "OverallStatus": [
                              "Completed"
                        ],
                        "OversightHasDMC": [
                              "No"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 4"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "August 1, 2020"
                        ],
                        "PrimaryCompletionDateType": [
                              "Actual"
                        ],
                        "PrimaryOutcomeDescription": [
                              "Any adverse events after the use of combination stem cell treatment would be recorded:\n\nBone marrow aspiration related complications such as pain (>6 on VAS) and bleeding from the site.\nLeukapheresis related complications such as hypotension and hypocalcemia.\nHepatic artery catheterization related complications such as pain or discomfort at the catheter insertion site, bleeding and infection.\nPost MSC and CD34 infusion related adverse reactions would be recorded using CDSCO form."
                        ],
                        "PrimaryOutcomeMeasure": [
                              "To assess the safety of combination of hematopoetic and mesenchymal stem cell in patients of liver cirrhosis."
                        ],
                        "NCTId": [
                              "NCT04243681"
                        ]
                  },
                  {
                        "Rank": 35,
                        "OverallOfficialName": [],
                        "OverallOfficialRole": [],
                        "OverallStatus": [
                              "Recruiting"
                        ],
                        "OversightHasDMC": [
                              "No"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Not Applicable"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "December 31, 2024"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [],
                        "PrimaryOutcomeMeasure": [
                              "Number of Participants with abnormal Total bilirubin",
                              "Number of Participants with abnormal albumin",
                              "Ishak Inflammation Rating System",
                              "Ishak Fibrosis Score"
                        ],
                        "NCTId": [
                              "NCT05106972"
                        ]
                  },
                  {
                        "Rank": 36,
                        "OverallOfficialName": [],
                        "OverallOfficialRole": [],
                        "OverallStatus": [
                              "Completed"
                        ],
                        "OversightHasDMC": [
                              "No"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Not Applicable"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "March 2013"
                        ],
                        "PrimaryCompletionDateType": [
                              "Actual"
                        ],
                        "PrimaryOutcomeDescription": [
                              "all patients will be transplanted bone marrow derived mesenchymal stem cells belonging to the opposite sex in order to genetically determine the mature hepatocyte"
                        ],
                        "PrimaryOutcomeMeasure": [
                              "differantiation of transplanted mesenchymal stem cells to hepatocytes in post treatment liver biopsies"
                        ],
                        "NCTId": [
                              "NCT01378182"
                        ]
                  },
                  {
                        "Rank": 37,
                        "OverallOfficialName": [
                              "YINGAN JIANG"
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Recruiting"
                        ],
                        "OversightHasDMC": [],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1",
                              "Phase 2"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "July 20, 2023"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [
                              "Parameters of liver stiffness",
                              "Change of Serum hepatic fibrosis indexes",
                              "Change of Serum hepatic fibrosis indexes",
                              "Change of Serum hepatic fibrosis indexes",
                              "Change of Serum hepatic fibrosis indexes",
                              "Status of the liver",
                              "Change of humoral immunity",
                              "Change of humoral immunity",
                              "Change of humoral immunity",
                              "Change of humoral immunity",
                              "Change of humoral immunity",
                              "Change of humoral immunity",
                              "Change of cellular immunity",
                              "Change of cellular immunity",
                              "Change of cellular immunity",
                              "Change of cellular immunity",
                              "Change of cellular immunity"
                        ],
                        "PrimaryOutcomeMeasure": [
                              "FibroScan",
                              "IV-C",
                              "HA",
                              "LN",
                              "PC-III",
                              "Hepatic histopathologic examination",
                              "IgG",
                              "IgA",
                              "IgM",
                              "IgE",
                              "C3",
                              "C4",
                              "CD3",
                              "CD4",
                              "CD8",
                              "CD19",
                              "CD16+56"
                        ],
                        "NCTId": [
                              "NCT05507762"
                        ]
                  },
                  {
                        "Rank": 38,
                        "OverallOfficialName": [
                              "Fu-Sheng Wang, Professor"
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Completed"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1",
                              "Phase 2"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "April 2016"
                        ],
                        "PrimaryCompletionDateType": [
                              "Actual"
                        ],
                        "PrimaryOutcomeDescription": [],
                        "PrimaryOutcomeMeasure": [
                              "survival time",
                              "incidence of HCC events"
                        ],
                        "NCTId": [
                              "NCT01220492"
                        ]
                  },
                  {
                        "Rank": 39,
                        "OverallOfficialName": [],
                        "OverallOfficialRole": [],
                        "OverallStatus": [
                              "Unknown status"
                        ],
                        "OversightHasDMC": [
                              "No"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Not Applicable"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "December 31, 2019"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [
                              "The absolute value change of ALP after 1 year of the initial stem cell treatment"
                        ],
                        "PrimaryOutcomeMeasure": [
                              "Change of alkaline phosphatase (ALP)"
                        ],
                        "NCTId": [
                              "NCT03668145"
                        ]
                  },
                  {
                        "Rank": 40,
                        "OverallOfficialName": [
                              "Moonyoung Kim"
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Recruiting"
                        ],
                        "OversightHasDMC": [
                              "No"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 3"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "March 2, 2026"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [
                              "Transplant free survival (TFS), the median survival time and 95% confidence interval for each group were presented using the Kaplan-Meier method, and the difference in the survival distribution between the two groups was used as a Cox proportional hazards model corrected for stratification Black."
                        ],
                        "PrimaryOutcomeMeasure": [
                              "Transplant free survival (TFS)"
                        ],
                        "NCTId": [
                              "NCT04689152"
                        ]
                  },
                  {
                        "Rank": 41,
                        "OverallOfficialName": [
                              "Jinhai Tang, M.D, PH.D"
                        ],
                        "OverallOfficialRole": [
                              "Study Chair"
                        ],
                        "OverallStatus": [
                              "Not yet recruiting"
                        ],
                        "OversightHasDMC": [],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1",
                              "Phase 2"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "March 1, 2025"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [
                              "The evaluation of serum levels of ALB",
                              "The evaluation of serum levels of ALT",
                              "The evaluation of serum levels of PA",
                              "The evaluation of serum levels of TB",
                              "The evaluation of serum levels of DB",
                              "The evaluation of serum levels of BUN",
                              "The evaluation of serum levels of UA",
                              "The evaluation of serum levels of Scr"
                        ],
                        "PrimaryOutcomeMeasure": [
                              "Albumin (ALB)",
                              "Alanine aminotransferase (ALT)",
                              "Prealbumin (PA)",
                              "Total bilirubin (TB)",
                              "Direct bilirubin (DB)",
                              "Blood urea nitrogen (BUN)",
                              "Uric acid (UA)",
                              "Serum creatinine (Scr)"
                        ],
                        "NCTId": [
                              "NCT03460795"
                        ]
                  },
                  {
                        "Rank": 42,
                        "OverallOfficialName": [
                              "Jun Cui, MD"
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Recruiting"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "December 25, 2022"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [
                              "According to the evaluation criteria of common adverse events (CTCAE v5.0), any AE occurred in all subjects during the clinical study, including abnormalities in clinical symptoms and vital signs and abnormalities in laboratory examination was observed.",
                              "According to the evaluation criteria of common adverse events (CTCAE v5.0), any AE occurred in all subjects during the clinical study, including abnormalities in clinical symptoms and vital signs and abnormalities in laboratory examination was observed.",
                              "According to the evaluation criteria of common adverse events (CTCAE v5.0), any AE occurred in all subjects during the clinical study, including abnormalities in clinical symptoms and vital signs and abnormalities in laboratory examination was observed.",
                              "According to the evaluation criteria of common adverse events (CTCAE v5.0), any AE occurred in all subjects during the clinical study, including abnormalities in clinical symptoms and vital signs and abnormalities in laboratory examination was observed.",
                              "According to the evaluation criteria of common adverse events (CTCAE v5.0), any AE occurred in all subjects during the clinical study, including abnormalities in clinical symptoms and vital signs and abnormalities in laboratory examination was observed.",
                              "According to the evaluation criteria of common adverse events (CTCAE v5.0), any AE occurred in all subjects during the clinical study, including abnormalities in clinical symptoms and vital signs and abnormalities in laboratory examination was observed.",
                              "According to the evaluation criteria of common adverse events (CTCAE v5.0), any AE occurred in all subjects during the clinical study, including abnormalities in clinical symptoms and vital signs and abnormalities in laboratory examination was observed.",
                              "According to the evaluation criteria of common adverse events (CTCAE v5.0), any AE occurred in all subjects during the clinical study, including abnormalities in clinical symptoms and vital signs and abnormalities in laboratory examination was observed.",
                              "According to the evaluation criteria of common adverse events (CTCAE v5.0), any AE occurred in all subjects during the clinical study, including abnormalities in clinical symptoms and vital signs and abnormalities in laboratory examination was observed."
                        ],
                        "PrimaryOutcomeMeasure": [
                              "Severity and incidence of adverse events (SIAE) on the 3rd day after the first administration",
                              "1 week SIAE after the first administration",
                              "3 weeks SIAE after the first administration",
                              "3 week SIAE after the the second administration",
                              "1 month SIAE after the last administration",
                              "3 months SIAE after the last administration",
                              "6 months SIAE after the last administration",
                              "12 months SIAE after the last administration",
                              "24 months SIAE after the last administration"
                        ],
                        "NCTId": [
                              "NCT05155657"
                        ]
                  },
                  {
                        "Rank": 43,
                        "OverallOfficialName": [
                              "Jianwu Dai, Ph.D"
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Unknown status"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1",
                              "Phase 2"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "December 2020"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [],
                        "PrimaryOutcomeMeasure": [
                              "Improvement of liver function measured by change in the model for end-stage liver disease (MELD) score"
                        ],
                        "NCTId": [
                              "NCT02786017"
                        ]
                  },
                  {
                        "Rank": 44,
                        "OverallOfficialName": [],
                        "OverallOfficialRole": [],
                        "OverallStatus": [
                              "Recruiting"
                        ],
                        "OversightHasDMC": [
                              "No"
                        ],
                        "PatientRegistry": [
                              "No"
                        ],
                        "Phase": [],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "December 31, 2022"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [
                              "An AE is any untoward medical event for the patient in the clinical study, associated with study medication. Any untoward event resulting in death, life threatening, requires hospitalization or prolongation of hospitalization, results in disability/incapacity, congenital anomaly/birth defect will be evaluated as an SAE."
                        ],
                        "PrimaryOutcomeMeasure": [
                              "Number of patients with adverse events (AEs) and serious AEs (SAEs)"
                        ],
                        "NCTId": [
                              "NCT03472742"
                        ]
                  },
                  {
                        "Rank": 45,
                        "OverallOfficialName": [
                              "Fu-Sheng Wang, professor"
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Unknown status"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1",
                              "Phase 2"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "October 2013"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [],
                        "PrimaryOutcomeMeasure": [
                              "Serum alkaline phosphatase (ALP)"
                        ],
                        "NCTId": [
                              "NCT01662973"
                        ]
                  },
                  {
                        "Rank": 46,
                        "OverallOfficialName": [
                              "Hamid Gourabi, PhD",
                              "Reza malekzadeh, MD",
                              "Massoud vosough, MD,PhD"
                        ],
                        "OverallOfficialRole": [
                              "Study Chair",
                              "Study Director",
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Completed"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "July 2013"
                        ],
                        "PrimaryCompletionDateType": [
                              "Actual"
                        ],
                        "PrimaryOutcomeDescription": [
                              "Evaluation of ALT levels during 12 months",
                              "Evaluation of AST levels after intervention during 12 months",
                              "The evaluation of serum albumin levels for 12 months",
                              "The decrease in grade of liver fibrosis"
                        ],
                        "PrimaryOutcomeMeasure": [
                              "ALT",
                              "AST",
                              "Serum Albumin",
                              "Liver Fibrosis"
                        ],
                        "NCTId": [
                              "NCT01454336"
                        ]
                  },
                  {
                        "Rank": 47,
                        "OverallOfficialName": [
                              "Juan Gallegos-Orozco, Ph.D"
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Unknown status"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "March 2021"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [
                              "An SAE suggests a significant hazard, contraindication, side-effect, or precaution. With respect to human clinical experience, this includes any event that:\n\nResults in death.\nIs life-threatening.*\nRequires in-patient hospitalization or prolongation of existing hospitalization.\nResults in persistent or significant disability/incapacity.\nIs a congenital anomaly/birth defect.\n\nOther medically important condition\n\nLife-threatening in the definition of a SAE or adverse reaction refers to an event in which the patient was at risk of death at the time of event; it does not refer to an event, which hypothetically might have caused death if it were more severe."
                        ],
                        "PrimaryOutcomeMeasure": [
                              "Incidence of Serious Adverse Events"
                        ],
                        "NCTId": [
                              "NCT03838250"
                        ]
                  },
                  {
                        "Rank": 48,
                        "OverallOfficialName": [
                              "Shuichi Kaneko, M.D."
                        ],
                        "OverallOfficialRole": [
                              "Study Chair"
                        ],
                        "OverallStatus": [
                              "Terminated"
                        ],
                        "OversightHasDMC": [],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "April 2010"
                        ],
                        "PrimaryCompletionDateType": [
                              "Actual"
                        ],
                        "PrimaryOutcomeDescription": [],
                        "PrimaryOutcomeMeasure": [
                              "all cause harmful events"
                        ],
                        "NCTId": [
                              "NCT00913289"
                        ]
                  },
                  {
                        "Rank": 49,
                        "OverallOfficialName": [
                              "Shuichi Kaneko, M.D."
                        ],
                        "OverallOfficialRole": [
                              "Study Chair"
                        ],
                        "OverallStatus": [
                              "Completed"
                        ],
                        "OversightHasDMC": [
                              "No"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Not Applicable"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "February 2015"
                        ],
                        "PrimaryCompletionDateType": [
                              "Actual"
                        ],
                        "PrimaryOutcomeDescription": [],
                        "PrimaryOutcomeMeasure": [
                              "all cause harmful events"
                        ],
                        "NCTId": [
                              "NCT01062750"
                        ]
                  },
                  {
                        "Rank": 50,
                        "OverallOfficialName": [
                              "Jinhai Tang, M.D, PH.D"
                        ],
                        "OverallOfficialRole": [
                              "Study Chair"
                        ],
                        "OverallStatus": [
                              "Unknown status"
                        ],
                        "OversightHasDMC": [],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1",
                              "Phase 2"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "March 1, 2020"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [
                              "The evaluation of serum levels of BUN",
                              "The evaluation of serum levels of Cr",
                              "The evaluation of serum levels of eGFR",
                              "The evaluation of serum levels of Cystatin C",
                              "The evaluation of serum levels of Urine protein"
                        ],
                        "PrimaryOutcomeMeasure": [
                              "BUN",
                              "Cr",
                              "eGFR",
                              "Cystatin C",
                              "Urine protein"
                        ],
                        "NCTId": [
                              "NCT03460223"
                        ]
                  },
                  {
                        "Rank": 51,
                        "OverallOfficialName": [],
                        "OverallOfficialRole": [],
                        "OverallStatus": [
                              "Recruiting"
                        ],
                        "OversightHasDMC": [
                              "No"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Early Phase 1"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "July 31, 2022"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [
                              "We compare this index in first day, 4th, 8th, 12th and 24th week, to describe their tendency.",
                              "We compare this index in first day, 4th, 8th, 12th and 24th week, to describe their tendency.",
                              "We compare this index in first day, 4th, 8th, 12th and 24th week, to describe their tendency.",
                              "We compare this index in first day, 4th, 8th, 12th and 24th week, to describe their tendency.",
                              "We compare this index in first day, 4th, 8th, 12th and 24th week, to describe their tendency.",
                              "We compare this index in first day, 4th, 8th, 12th and 24th week, to describe their tendency.",
                              "We compare this index in first day, 4th, 8th, 12th and 24th week, to describe their tendency.",
                              "We compare this index in first day, 4th, 8th, 12th and 24th week, to describe their tendency.",
                              "We compare this index in first day, 4th, 8th, 12th and 24th week, to describe their tendency."
                        ],
                        "PrimaryOutcomeMeasure": [
                              "Serum albumin in g/L",
                              "alanine aminotransferase in U/L",
                              "aspartate aminotransferase in U/L",
                              "cholinesterase in U/L",
                              "Total bilirubin in \u03bcmol/L",
                              "Direct bilirubin in \u03bcmol/L",
                              "Serum cholesterol in mmol/L",
                              "Prothrombin activity in percentage",
                              "Antithrombin in mg/L"
                        ],
                        "NCTId": [
                              "NCT05442437"
                        ]
                  },
                  {
                        "Rank": 52,
                        "OverallOfficialName": [
                              "Isao Sakaida, MD, PhD"
                        ],
                        "OverallOfficialRole": [
                              "Study Chair"
                        ],
                        "OverallStatus": [
                              "Unknown status"
                        ],
                        "OversightHasDMC": [
                              "No"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "March 2017"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [],
                        "PrimaryOutcomeMeasure": [
                              "The incidence of adverse events"
                        ],
                        "NCTId": [
                              "NCT02327832"
                        ]
                  },
                  {
                        "Rank": 53,
                        "OverallOfficialName": [
                              "Lin B Liang, MD/PHD"
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Unknown status"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 2"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "November 2011"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [],
                        "PrimaryOutcomeMeasure": [
                              "Liver Function"
                        ],
                        "NCTId": [
                              "NCT01223664"
                        ]
                  },
                  {
                        "Rank": 54,
                        "OverallOfficialName": [
                              "Reza Malekzadeh, M.D.",
                              "Hamid Goorabi, Phd",
                              "Mehdi Mohamadnejad, M.D.",
                              "Hossein Baharvand, Phd"
                        ],
                        "OverallOfficialRole": [
                              "Study Chair",
                              "Study Chair",
                              "Principal Investigator",
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Completed"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "May 2008"
                        ],
                        "PrimaryCompletionDateType": [
                              "Actual"
                        ],
                        "PrimaryOutcomeDescription": [],
                        "PrimaryOutcomeMeasure": [
                              "Serum cholesterol and LDL levels"
                        ],
                        "NCTId": [
                              "NCT00515307"
                        ]
                  },
                  {
                        "Rank": 55,
                        "OverallOfficialName": [
                              "Yves Beguin, MD, PhD"
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Completed"
                        ],
                        "OversightHasDMC": [
                              "No"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1",
                              "Phase 2"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "March 11, 2019"
                        ],
                        "PrimaryCompletionDateType": [
                              "Actual"
                        ],
                        "PrimaryOutcomeDescription": [
                              "Incidence, timing and severity of any clinical complication related to MSC infusion, including pulmonary events or immune reactions.",
                              "Incidence, timing and severity of any infection (bacterial, viral, fungal, parasitic) (blood hemoculture, urine culture, PCR CMV, PCR BK virus at month 1,2,3)\nIncidence, timing and severity of malignant disease (Posttransplant lymphoproliferative disorder or other)"
                        ],
                        "PrimaryOutcomeMeasure": [
                              "Infusional toxicity",
                              "Incidence of infections (bacterial, viral, fungal, parasitic) and cancers"
                        ],
                        "NCTId": [
                              "NCT01429038"
                        ]
                  }
            ]
      }
}